Shots: The P-III ARAMIS study involves assessing of Nubeqa (600mg, bid) + ADT vs PBO + ADT in 1,509 patients in a ratio (2:1) with nmCRPC who were receiving a concomitant GnRH analog or had a bilateral orchiectomy The P-III ARAMIS study resulted in meeting its 1EPs i.e, improvement in MFS (40.4 vs 18.4mos.) Nubeqa […]Read More
Shots: The P-III ARAMIS trial involves assessing of Darolutamide (600 mg, bid) + androgen deprivation therapy (ADT) vs PBO + ADT in 1509 patients in the ratio (2:1) with nmCRPC P-III ARAMIS study results: mMFS (40.4 vs 18.4 mos.); 59% reduction in risk of metastasis or death; time to pain progression (40.3 vs 25.4 mos.); […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
